Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Itezocabtagene autoleucel by Tessa Therapeutics for Primary Mediastinal B-Cell Lymphoma: Likelihood of Approval
Itezocabtagene autoleucel is under clinical development by Tessa Therapeutics and currently in Phase I for Primary Mediastinal B-Cell Lymphoma. According...
Itezocabtagene autoleucel by Tessa Therapeutics for Natural Killer Cell Lymphomas: Likelihood of Approval
Itezocabtagene autoleucel is under clinical development by Tessa Therapeutics and currently in Phase I for Natural Killer Cell Lymphomas. According...
Itezocabtagene autoleucel by Tessa Therapeutics for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
Itezocabtagene autoleucel is under clinical development by Tessa Therapeutics and currently in Phase I for Diffuse Large B-Cell Lymphoma. According...
Itezocabtagene autoleucel by Tessa Therapeutics for Non-Hodgkin Lymphoma: Likelihood of Approval
Itezocabtagene autoleucel is under clinical development by Tessa Therapeutics and currently in Phase II for Non-Hodgkin Lymphoma. According to GlobalData,...
Itezocabtagene autoleucel by Tessa Therapeutics for Peripheral T-Cell Lymphomas (PTCL): Likelihood of Approval
Itezocabtagene autoleucel is under clinical development by Tessa Therapeutics and currently in Phase I for Peripheral T-Cell Lymphomas (PTCL). According...
Itezocabtagene autoleucel by Tessa Therapeutics for Anaplastic Large Cell Lymphoma (ALCL): Likelihood of Approval
Itezocabtagene autoleucel is under clinical development by Tessa Therapeutics and currently in Phase I for Anaplastic Large Cell Lymphoma (ALCL)....
Itezocabtagene autoleucel by Tessa Therapeutics for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma): Likelihood of Approval
Itezocabtagene autoleucel is under clinical development by Tessa Therapeutics and currently in Phase II for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)....